Evidence map›Paper›PMID 41629675›Full record

Articlenpj antimicrobials and resistance2026

Survival of ampicillin-treated uropathogenic Escherichia coli is independent of single-cell growth rates.

Yoshiko Miyahara, François Signorino-Gelo, Nicolas Elian Michel Lonchampt, Paul Murima, John D McKinney, Neeraj Dhar

Abstract read
In one paragraph

Article in npj antimicrobials and resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yoshiko Miyahara *Global Health Institute, School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
François Signorino-GeloGlobal Health Institute, School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
Nicolas Elian Michel LonchamptGlobal Health Institute, School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
Paul MurimaGlobal Health Institute, School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
John D McKinneyGlobal Health Institute, School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. john.mckinney@epfl.ch.
Neeraj Dhar *Global Health Institute, School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. neeraj.dhar@usask.ca.

Funding

CIHR ARB 192058Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_156945Seventh Framework Programme 115337
6 · The paper itself

Abstract

The refractoriness of persistent infections to antibiotics necessitates lengthy treatment regimens to prevent therapeutic failures and relapses. Persistence has been attributed to entry of a small fraction of bacterial cells into a slowly growing or non-growing physiological state, which is thought to protect them against antibiotics targeting growth-related processes. However, these conclusions are largely based on studies conducted with lab-adapted strains carrying mutations that confer abnormally high levels of persistence. Here, we perform single-cell studies of ampicillin-mediated killing and persistence in a clinical isolate of uropathogenic Escherichia coli (UPEC). We show that the majority of surviving cells are growing and dividing normally at the time of ampicillin exposure. Conversely, we find that the majority of non-growing cells are readily killed by ampicillin exposure. These findings challenge the widespread assumption that bacterial dormancy and persistence are inextricably linked.

Identifiers

PMID41629675
PMCPMC12864937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.